Humacyte Inc (HUMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Humacyte Inc (HUMA) Competitors
The companies most similar to Humacyte are TuHURA Biosciences (HURA), Whitehawk Therapeutics (WHWK) and Unicycive Therapeutics (UNCY). By market cap, Humacyte ranks 5th of the 13 companies on this page; Inhibikase Therapeutics (IKT) is the largest at $213.21M.
Peer Comparison
HUMA's ROIC of -60.5% is above the peer median of -81.8%, and its revenue growth of 36.5% is above the median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Humacyte (HUMA) | $155.12M | N/A | 62.6x | 0.0% | -60.5% | 36.5% | 0.00% |
| TuHURA Biosciences Inc (HURA) | $88.58M | N/A | N/A | 0.0% | -81.8% | 0.0% | 0.00% |
| Whitehawk Therapeutics, Inc. (WHWK) | $180.57M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Unicycive Therapeutics Inc (UNCY) | $97.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Coherus BioSciences Inc (CHRS) | $81.21M | N/A | 1.5x | -253.4% | -144.8% | 23.4% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Foghorn Therapeutics Inc (FHTX) | $124.12M | 40.1x | 1.1x | 8.4% | N/A | 925.0% | 0.00% |
| Vivani Medical Inc. (VANI) | $91.11M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Zura Bio Limited Class A Ordinary Shares (ZURA) | $119.44M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| enGene Therapeutics Inc. (ENGN) | $161.51M | N/A | N/A | 0.0% | -42.2% | 0.0% | 0.00% |
| Inhibikase Therapeutics Inc (IKT) | $213.21M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $121.78M | 40.1x | 1.5x | 0.0% | -81.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Humacyte, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| TuHURA Biosciences Inc (HURA) | TuHURA Biosciences Inc is a pioneering biotechnology firm committed to advancing immunotherapy solutions for cancer and autoimmune diseases. | HURA competitors |
| Whitehawk Therapeutics, Inc. (WHWK) | Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. | WHWK competitors |
| Unicycive Therapeutics Inc (UNCY) | Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases... | UNCY competitors |
| Coherus BioSciences Inc (CHRS) | Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. | CHRS competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Foghorn Therapeutics Inc (FHTX) | Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within... | FHTX competitors |
| Vivani Medical Inc. (VANI) | Vivani Medical Inc. (VANI) is a pioneering biotechnology firm focused on revolutionizing chronic disease management through its cutting-edge drug delivery... | VANI competitors |
| Zura Bio Limited Class A Ordinary Shares (ZURA) | Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. | ZURA competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| enGene Therapeutics Inc. (ENGN) | enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery... | ENGN competitors |
| Inhibikase Therapeutics Inc (IKT) | Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside... | IKT competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
Frequently Asked Questions About HUMA
Who are Humacyte's main competitors?
The companies most similar to Humacyte include TuHURA Biosciences (HURA), Whitehawk Therapeutics (WHWK), Unicycive Therapeutics (UNCY), Coherus BioSciences (CHRS) and Immunic (IMUX), listed from the closest match.
Who is Humacyte's biggest competitor?
Inhibikase Therapeutics (IKT) is the largest of the similar companies at $213.21M; TuHURA Biosciences (HURA) is the closest match by business profile, size, sector and industry.
How does HUMA stock compare with its competitors?
HUMA's P/S is 62.6x against a peer median of 1.5x; its net margin is 0.0% against a peer median of 0.0%.
Which of Humacyte's competitors pays a higher dividend?
Humacyte pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Humacyte bigger than its competitors?
No. Humacyte is 5th by market cap among the 13 companies on this page; the largest is Inhibikase Therapeutics (IKT) at $213.21M.
HUMA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors